SCHEMBL23782

SCHEMBL23782

Cc1cccc(C(=O)N(C)C)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.65
TDP1 Q9NUW8 1/20 0.65
PARP1 P09874 1/20 0.59
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.52
KCNK3 O14649 3/20 0.50
KCNK9 Q9NPC2 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KCNH2 Q12809 1/20 0.50
POLB P06746 2/20 0.49
ABCB1 P08183 1/20 0.47
ERN1 O75460 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HSD17B1 P14061 1/20 0.46
HSD17B2 P37059 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29637011 1.00 HPGD (0.65) HPGDTDP1PARP1HDAC8HDAC6
SCHEMBL7406706 0.87 MEN1 (0.55) HPGDTDP1SMN1; SMN2MEN1KMT2A
SCHEMBL6675237 0.86 HPGD (0.62) HPGDTDP1PARP1HDAC8HDAC6
SCHEMBL9100257 0.84 HPGD (0.61) HPGDTDP1PARP1HDAC8HDAC6
SCHEMBL6832775 0.84 HPGD (0.61) HPGDTDP1PARP1HDAC8HDAC6
SCHEMBL1759401 0.83 HPGD (0.65) HPGDTDP1PARP1HDAC8HDAC6
SCHEMBL11913144 0.82 HPGD (0.74) HPGDTDP1PARP1HDAC8HDAC6
SCHEMBL11675937 0.82 HPGD (0.62) HPGDTDP1PARP1HDAC8HDAC6
SCHEMBL25908515 0.82 HPGD (0.62) HPGDTDP1PARP1HDAC8HDAC6
SCHEMBL3658429 0.81 HPGD (0.62) HPGDTDP1PARP1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3175865-B1 FUNCTIONAL PARTICLES, PROCESS TO OBTAIN THEM, AND THEIR APPLICATIONS SMART INOVATION LDA (PT) 2026-04-15 EP claimed
CN-107249322-B Method for inhibiting penetration of pest repellent into skin and penetration inhibitor for inhibiting penetration of pest repellent into skin 阿斯制药株式会社 2021-10-26 CN claimed
EP-3763212-B1 ARTHROPODA REPELLENT COMPOSITION SANDERSTROTHMANN GMBH (DE) 2021-08-18 EP claimed
US-11013809-B2 Sustained delivery formulations of risperidone compound INDIVIOR UK LIMITED (GB) 2021-05-25 US claimed
WO-2018136909-A1 PREPARATION OF MICROPARTICLES OF AN ACTIVE INGREDIENT SAVIOR LIFETEC CORPORATION (TW) 2018-07-26 WO claimed
US-20180157440-A1 INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE INDIVIOR INC. 2018-06-07 US claimed
US-20180020667-A1 CHEMICAL COMPOSITIONS THAT PRESENT SYNERGIC EFFECT FOR REPELLENCY OF INSECTS IN PERSONAL HYGIENE PRODUCTS, COSMETICS FOR HUMAN USE, IN ANIMALS AND ON INANIMATE SURFACES IN GENERAL UNIVERSAL CHEMICAL LTDA. (BR) 2018-01-25 US claimed
EP-3272218-A1 CHEMICAL COMPOSITIONS THAT PRESENT SYNERGIC EFFECT FOR REPELLENCY OF INSECTS IN PERSONAL HYGIENE PRODUCTS, COSMETICS FOR HUMAN USE, IN ANIMALS AND ON INANIMATE SURFACES IN GENERAL Universal Chemical Ltda (BR) 2018-01-24 EP claimed
US-20170225958-A1 FUNCTIONAL PARTICLES, PRODUCTION PROCESS AND USES SMART INOVATION, LDA (PT) 2017-08-10 US claimed
EP-3175865-A1 FUNCTIONAL PARTICLES, PRODUCTION PROCESS AND USES Smart Inovation Lda (PT) 2017-06-07 EP claimed
EP-1126822-A1 CONTROLLED RELEASE LIQUID DELIVERY COMPOSITIONS WITH LOW INITIAL DRUG BURST ATRIX LABORATORIES, INC. (US) 2001-08-29 EP claimed
US-6211389-B1 TREATING SPECIFICALLY DEFINED COMBINATIONS COMPRISING AN EPOXY RESIN STARTING MATERIAL AND OTHER COMPONENTS TO ORGANIC SOLVENT, A CROWN ETHER, AND A SUITABLE BASE TO CONDITIONS SUFFICIENT TO PRODUCE A TREATED EPOXY COMPOUND DEXTER CORPORATION 2001-04-03 US claimed
US-6143314-A THERMOPLASTIC RESIN ATRIX LABORATORIES, INC. (US) 2000-11-07 US claimed
WO-2000038512-A1 METHOD AND APPARATUS FOR DISPERSING A VOLATILE COMPOSITION UNIVERSITY OF SOUTHAMPTON (GB) 2000-07-06 WO claimed
WO-2000024374-A1 CONTROLLED RELEASE LIQUID DELIVERY COMPOSITIONS WITH LOW INITIAL DRUG BURST ATRIX LABORATORIES, INC. (US) 2000-05-04 WO claimed
US-5888533-A Non-polymeric sustained release delivery system ATRIX LABORATORIES, INC. (US) 1999-03-30 US claimed
EP-0525893-B1 The use of an aqueous hard surface cleaner containing an insect repellent material COLGATE PALMOLIVE CO (US) 1999-02-24 EP claimed
US-5736152-A Non-polymeric sustained release delivery system ATRIX LABORATORIES, INC. (US) 1998-04-07 US claimed
EP-0754064-A1 AN ADJUNCTIVE POLYMER SYSTEM FOR USE WITH MEDICAL DEVICE ATRIX LABORATORIES, INC. (US) 1997-01-22 EP claimed
WO-1995028124-A2 AN ADJUNCTIVE POLYMER SYSTEM FOR USE WITH MEDICAL DEVICE ATRIX LABORATORIES, INC. (US) 1995-10-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11013809-B2 Sustained delivery formulations of risperidone compound SLC6A3, GRIN2A, GRIN2D HPGD 2124/4885TDP1 1172/4885PARP1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.